Tandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.44), $0.04 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $21.3 million versus the consensus estimate of $21.74 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.